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Abstract 
Case report on KMT2A-CBL Fusion Gene Resulting 
from del(11)(q23.3q23.3) Identified by 
Chromosome Microarray Analysis - second report in 
AML 
Clinics 
Age and sex: 18 years old female patient. 
Previous history: no preleukemia, no previous 
malignancy ; no inborn condition of note  
Organomegaly: no hepatomegaly, no splenomegaly 
, no enlarged lymph nodes , no central nervous 
system involvement  
Blood 
WBC: 1.3 (neut 0.1x109/L);X 109/l 
HB: 7.4g/dl 
Platelets: 55X 109/l 
Note 
The marrow smears showed heavily infiltrated with 
medium sized cells, which are round, have minimal 
lightly basophilic agranular cytoplasm and 
inconspicuous nucleoli, with partially clumped 
nuclear chromatin. Some of the nuclei appear 
cleaved or folded. A minority of the cells has very 
immature chromatin and/or prominent nucleoli, and 
are more classically blasts. There are no Auer rods in 
either population. Very minimal evidence of 
maturing granulopoiesis and erythropoiesis is seen. 
Granulopoesis appears to have normal granulation. 
Erythropoiesis appears normoblastic and not grossly 
dysplastic.  
Some of the mature neutrophils appear dysplastic 
with abnormal nuclear stranding. Megakaryocytes 
are not seen. 
Cyto-Pathology 
Classification 
Phenotype AML with 'recurrent cytogenetic 
translocations' 
Immunophenotype CD45lo/ SSClo blasts account 
for 61.2% of total BM intact single cells. Positive 
for: CD34, CD33, CD15, CD38, CD56, HLADR. By 
intracellular staining, these cells were entirely 
cCD34+ and 45% were cMPO+. These cells were 
negative for: TdT, cCD3- and cCD79a-. 
Rearranged Ig Tcr Not performed 
Pathology Not performed 
Electron microscopy Not performed 
Diagnosis Common Acute Myeloid Leukaemia. 
Survival 
Date of diagnosis 05-2017 
Treatment according to FLAG-Ida chemotherapy 
protocol. 
Complete remission:  Complete remission was 
obtained on 06/2017 
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Treatment related death: no   
Relapse: no   
Status: Alive 
Last follow up: 08-2019 
Survival: 26 months + 
Karyotype 
Sample Bone marrow 
Culture time 24h 
Banding GTG 
Results 
46,XX[20] - All 20 G-banded metaphase cells 
analysed showed a female karyotype with no 
apparent cytogenetic abnormalities. 
Other molecular cytogenetics technics 
1. FISH analysis was performed screening for 
cryptic chromosome rearrangements using the 
commercial dual colour break apart KMT2A (MLL) 
and dual colour dual fusion CBFB-MYH11 probes 
(both Cytocell, Cambridge, UK) following routine 
protocol to look for aberrations involving 11q23.3 
and for the presence of inv(16)/t(16;16) respectively.  
2. Chromosome microarray analysis (CMA) was 
performed using 8x60K oligonucleotide arrays 
(Agilent) analyzed with Agilent Genomic 
Workbench v 7.0 (settings: ADM2, threshold 6, 3 
consecutive probes) at an average resolution of 
50Kb.  
The patient's DNA was hybridized against 
commercially available same-sex control DNA 
(Promega) as done before (Nacheva et al., 2013).  
3. The target myeloid gene panel TruSight on a 
MiSeq platform (Illumina, USA) was used to screen 
mutational hotspots of 54 cancer-related genes 
relevant in myeloid malignancy as before (Boneva et 
al., 2017). Gene variances were reported at allele 
frequencies (VAF) >10% and at minimum read 
depth of 300 as per manufacturers criteria. We used 
the Catalogue of Somatic Mutations In Cancer 
(COSMIC), dbSNP and 1000 genome (>2%) to 
classify gene variants as either drivers, variants of 
unknown significance and/or germline 
polymorphisms (SNPs). Genome addresses are 
given according to hg19 (GRCH37) 
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Other molecular cytogenetics results 
 FISH:  nuc ish11q23(5'KMT2Ax2,3'KMT2Ax1) 
(5'KMT2Acon3'KMT2Ax1)[92/100], 
16p13.11(MYH11x2),16q22.1(CBFBx2)[100].    
Out of the 100 cells analysed, 92 showed an 
abnormal signal pattern for KMT2A indicative for 
interstitial deletion of the 3' site of the KMT2A gene 
probe [figure 1a]. All 100 cells analysed were 
negative for CBFB-MYH11 rearrangement.  
 CMA:  arr[GRCh37] 11q23.3 
(118355060_119103310)x1 (748Kb).    Whole 
genome scan identified a female genome with two 
SNP polymorphic markers reported in normal 
individuals at the Database of Genomic Variants 
(DGV; http://dgv.tcag.ca) and a 748Kb deletion 
within the 11q23.3 region, commencing at 
chr11:118,355,060 and terminating at 
chr11:119,103,310 [figure 1b-d]. The genome loss 
includes 47.855bp from the 5' part of KMT2A and 
26.324bp from the 3' part of the CBL gene likely 
resulting in formation of a KMT2A-CBL fusion as 
described before (Huret et al., 2013; Meyer et al., 
2018).  
 Variants:  The only mutation identified in this 
sample is a missense variance of the RUNX1 gene 
(NP_001745.2:p.Gly372Ser at 36164761) which is 
reported SNV which is  predicted to be tolerated' 
(http://cancer.sanger.ac and 
http://www.ncbi.nlm.nih. gov/SNP) and therefore 
considered indicative for disease only in the 
presence of cell morphology and 
immunophenotyping evidence   (Genovese et al., 
2014; Cargo et al., 2015 and reviewed in Steensma, 
2018). 
Comments 
The most common rearrangements of the KMT2A 
gene are reciprocal chromosome translocations and 
their prognostic relevance is well established, but 
deletions of the same region leading to KMT2A 
fusion rearrangements are rare and little is known 
about their prognostic significance.  
We describe the second case of AML with extremely 
rare 5'KMT2A-3'BCL fusion gene resulting from 
interstitial cryptic loss (748Kb) within the 11q23.3 
chromosome region identified by FISH and CMA 
analysis. The first case of adult AML, which was 
reported in 2003, affected a 29-year-old female 
patient (Fu et al., 2003; also reported in Shih et al., 
2006 and in Huret, 2013). In the previous report, the 
authors demonstrated that the hybrid gene 
(5'KMT2A-3'CBL) is the result of loss of 3'of 
KMT2A with breakpoint in exon 9 and fusion whit 
exon 8 of CBL gene. In present case, we used FISH 
and CMA to demonstrate interstitial deletion of the 
3' region of the KMT2A gene. We therefore assume 
that the loss of 3' part of KMT2A  
gene leads to 5' KMT2A -3'CBL fusion as described. 
What is the prognostic impact of this fusion gene is 
still unclear. Our patient has achieved complete 
remission with chemotherapy for 26 months. In both 
previous and present cases, the fusion 5' KMT2A -
3'CBL gene results from a cryptic genome loss, the 
detection of which is beyond G banding resolution 
and leaves the chromosome 11 banding pattern 
intact.  Of a note, the KMT2A-CBL fusion was also 
described in T-ALL resulting form 
t(11;11)(q23;q23).  
The presented case provides further support to the 
investigative power of CMA and a reminder for the 
existence of rare and possibly recurrent 5' KMT2A -
3'CBL fusion gene in adult AML. 
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